A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

Exclusion criteria

• ✕. Clinically significant gastroparesis or a history of bariatric surgery.
• ✕. Bowel obstruction, swallowing disorders, severe gastrointestinal disorders, including inflammatory bowel disease, major gastrointestinal surgery, or known active gastric/duodenal ulcers.
• ✕. Severe recurrent diarrhea or severe recurrent constipation, in the opinion of the Investigator.
• ✕. Pernicious anemia, atrophic or autoimmune gastritis, achlorhydria or hypochlorhydria.
• ✕. Carcinoma in situ (e.g., of the cervix, breast, or bladder) that has been completely excised and shows no evidence of residual disease.
• ✕. Non-melanoma skin cancers (e.g., basal cell carcinoma, squamous cell carcinoma) that have been completely excised and show no evidence of recurrence.
• ✕. Low grade prostate cancer, in the opinion of the Investigator (i.e., no metastasis, Gleason score \< 6), with no significant worsening for \> 6 months prior to the screening visit.
• ✕. Any other malignancy that was treated with curative intent and has been in complete remission for ≥ 5 years prior to the screening visit.